Cardiovascular effects of hormone therapy for prostate cancer

Mason, Malcolm David ORCID: https://orcid.org/0000-0003-1505-2869 and Lester, Jason 2015. Cardiovascular effects of hormone therapy for prostate cancer. Drug, Healthcare and Patient Safety 7 , pp. 129-138. 10.2147/DHPS.S50549

Full text not available from this repository.

Abstract

Androgen deprivation therapy (ADT) has been the mainstay of treatment for advanced prostate cancer for decades, and has been shown to control disease and improve symptoms. In addition, for men with high-risk localized or locally advanced prostate cancer, short-course ADT in combination with radiotherapy improves survival. There is evidence that ADT increases cardiovascular risk, particularly in men with preexisting cardiovascular disease. This increased risk may apply even with short-course ADT. In an individual patient, the benefits of ADT should be balanced against the risk, and patients who require ADT should have risk factors for cardiovascular disease optimized. There is some evidence to suggest that more contemporary methods of delivering ADT may reduce cardiovascular risk.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords:	androgen deprivation therapy, testosterone, cardiovascular risk, hypercoagulability, prostate cancer patients, dihydrotestosterone, androgen receptor
Publisher:	Dove Press Ltd
ISSN:	1179-1365
Date of Acceptance:	30 April 2015
Last Modified:	31 Oct 2022 10:47
URI:	https://orca.cardiff.ac.uk/id/eprint/86176

Citation Data

Cited 22 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item